Back to News
Mar 3, 2026 4:11 PM

AI-Powered Tempus Inks New Multi-Year Merck Deal

Tempus AI Inc. (NASDAQ:TEM) on Tuesday inked a strategic collaboration agreement with Merck & Co. Inc. (NYSE:MRK) aimed at accelerating AI-driven precision medicine.

The stock’s decline comes as broader markets experienced significant sell-offs, with major indices like the S&P 500 and Nasdaq both trading lower today.

Tempus announced an expanded, multi-year collaboration with Merck to enhance the discovery and development of precision medicine biomarkers.

The partnership will leverage Tempus’ extensive library of de-identified multimodal data and its advanced Lens Platform, which utilizes one of the industry’s largest GPU infrastructures for complex analyses.

The collaboration is expected to support Merck’s oncology and potentially broader therapeutic portfolios, allowing for the identification of novel precision biomarkers and mechanisms of cancer cell resistance.

The strategic move underscores Tempus’ commitment to integrating AI technologies into healthcare, aiming to improve ...